Animal only
This mouse study investigated whether adjunctive thymosin beta-4 (Tβ4) combined with the antibiotic ciprofloxacin could restore corneal nerve integrity and visual function following Pseudomonas aeruginosa bacterial keratitis, a serious eye infection. Researchers induced keratitis in C57BL/6 mice by inoculating wounded corneas with P. aeruginosa, then administered one of four topical treatments three times daily beginning 24 hours post-infection: PBS (vehicle control), Tβ4 alone, ciprofloxacin alone, or Tβ4 combined with ciprofloxacin. Outcomes assessed included clinical disease severity, visual acuity, contrast sensitivity, corneal sensitivity (nerve function), and corneal nerve density/architecture via β-III tubulin immunofluorescence. The study found that the combination of Tβ4 and ciprofloxacin outperformed all monotherapy and control groups across every measured outcome, restoring nerve density and visual function to levels comparable to uninfected controls. Key limitations include the exclusive use of an animal model, meaning findings may not directly translate to humans, and the study does not address long-term safety, optimal treatment windows, or clinical feasibility. These results suggest Tβ4 may be a promising adjunctive therapy warranting further investigation.
Investigative ophthalmology & visual science · Jun 2026DOI ↗ ReviewPreprint
This scoping review systematically mapped the published and registered evidence on Thymosin Beta-4 (TB4) and the related synthetic peptide TB-500 in tissue healing, regeneration, and musculoskeletal repair. Searching PubMed, Europe PMC, and ClinicalTrials.gov through March 2026, the authors identified 1,772 records and included 80 studies after screening. Key findings include: (1) the evidence base is heavily skewed toward in vitro and animal (preclinical) designs rather than human trials; (2) most research has examined TB4, while direct evidence on TB-500 was limited to a single included study; (3) the most studied tissue categories were wound/skin/soft tissue, vascular/endothelial, and ocular/corneal, with the strongest human evidence concentrated in ocular and wound-healing contexts; and (4) musculoskeletal-specific tissues—such as tendon, ligament, muscle, cartilage, and intervertebral disc—were comparatively underrepresented. The authors concluded that while the literature supports interest in several repair-related biological pathways, it remains unevenly distributed and largely preclinical, and does not yet provide a robust human evidence base for musculoskeletal applications. Scoping reviews do not perform meta-analyses or quality appraisal of individual studies, which limits causal conclusions.
Unknown journal · May 2026DOI ↗ InsufficientPreprint
This study analyzed a large, publicly available independent testing dataset of 6,441 samples spanning fourteen peptide compounds sold through largely unregulated gray market channels directly to consumers. Compounds examined included BPC-157, semaglutide, tirzepatide, PT-141, TB-500, thymosin beta-4, and others marketed for purposes such as injury recovery, muscle growth, fat loss, and athletic performance. Researchers applied two quality acceptance frameworks — one approximating standards for 503A compounded medications and a stricter model reflecting FDA-approved drug production standards — to assess purity, measured abundance, and endotoxin burden. The study found that between 41.6% and 71.1% of samples failed to meet basic quality criteria depending on the framework applied, and measurable endotoxin contamination was detected in 15% of samples. Gray market peptides were consistently cheaper than FDA-approved alternatives, though cost differentials varied widely (e.g., 72.8% higher for tirzepatide vs. 3,850% higher for PT-141 when comparing FDA-approved options). The authors concluded that consumer-directed third-party testing improves transparency but captures only a fraction of the full safety profile relevant to patients self-administering injectable compounds. Key limitations include reliance on a secondary dataset not collected under controlled research conditions and the inability to assess many other safety dimensions beyond purity and endotoxin levels.
Unknown journal · Apr 2026DOI ↗ Review
This narrative review examines the pharmacological mechanisms, safety profiles, and regulatory status of twelve peptides commonly marketed in sports medicine contexts, spanning both FDA-approved compounds (e.g., tesamorelin/Egrifta) and unapproved "gray market" substances (e.g., BPC-157, CJC-1295, TB-500, ipamorelin, and others). The authors note that while many unapproved peptides show promising tissue repair and metabolic effects in animal models, rigorous human safety and efficacy data are largely absent. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses the potential for serious patient harm. Notably, the authors address the placebo effect as a possible mediator of perceived peptide efficacy and examine how social media may amplify this effect. A clinician-oriented framework is proposed to guide evidence-based patient discussions about peptide use for musculoskeletal healing and athletic performance, including consideration of alternative treatments. Key limitations include the narrative (non-systematic) review methodology and the inherently limited and heterogeneous evidence base for most compounds discussed, particularly in human populations.
Sports medicine (Auckland, N.Z.) · Apr 2026DOI ↗ ReviewPreprint
This narrative review examines the pharmacological mechanisms, safety profiles, and regulatory status of twelve peptides commonly encountered in sports medicine and athletic performance contexts, including both approved agents (e.g., tesamorelin/Egrifta, sermorelin) and unapproved "gray market" compounds (e.g., BPC-157, CJC-1295, TB-500, ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, SS-31, and thymosin beta-4). The authors note that while many unapproved peptides show promising tissue repair and metabolic outcomes in animal models, rigorous human safety and efficacy data remain scarce. The review highlights the emergence of a direct-to-consumer gray market operating outside regulatory oversight and the potential for serious patient harm. It further discusses the placebo effect as a potential mediator of perceived peptide efficacy, and how social media may amplify this effect. The authors provide a clinical framework to guide patient-provider discussions and promote evidence-based practice for musculoskeletal healing. Key limitations include the narrative (non-systematic) review design, reliance on preclinical literature for most unapproved compounds, and the absence of head-to-head human trials for the majority of agents discussed.
Unknown journal · Apr 2026DOI ↗ Review
This comprehensive narrative review examines nine therapeutic peptides with proposed applications in healthy aging and age-related conditions: tirzepatide (metabolic dysfunction), epitalon (telomere biology), GHK-Cu (dermal regeneration), BPC-157 and TB-500 (tissue repair), Semax (neuroprotection), CJC-1295 and ipamorelin (growth hormone modulation), and bremelanotide (sexual function). The authors searched PubMed, Scopus, and regulatory databases through January 2026, selecting 20 primary sources based on relevance and methodological quality. The review found that FDA-approved agents such as tirzepatide and bremelanotide have robust safety and efficacy data from large-scale trials, while investigational peptides such as epitalon, BPC-157, and TB-500 show promising signals primarily from preclinical and limited clinical studies. The authors highlight significant knowledge gaps, including the absence of long-term safety data for non-approved peptides, undefined optimal dosing regimens, unknown combination therapy effects, and lack of validated biomarkers for monitoring efficacy. The authors conclude that while therapeutic peptides offer mechanistically diverse approaches to aging hallmarks, investigational agents require rigorous clinical trial validation before clinical adoption. As a narrative review, findings are subject to selection bias and do not represent a quantitative synthesis of evidence.
Frontiers in aging · Apr 2026DOI ↗ In vitro
This study investigated how different photoaffinity crosslinkers influence the biological activity, labeling efficiency, and target protein preference of quinazolinone-based active molecules—specifically QDAU5, a compound previously shown to promote vascular normalization. The researchers constructed a library of photocrosslinkers and multifunctional photoaffinity probes using structures such as thiophene-substituted α-ketoamide, tetrazole, isoxazole, and 2-nitrobenzyl alcohol, then applied Photoaffinity Labeling–Affinity-Based Protein Profiling (PAL-AfBPP) combined with proteomic analysis to assess probe performance. Prior work had identified EphrinB2 as an intracellular target of QDAU5; this study further validated Thymosin β4 (Tβ4) as an additional potential target and began characterizing how QDAU5 interacts with Tβ4 at a molecular level. The findings suggest that the choice of photocrosslinker meaningfully affects both the retained bioactivity of the parent compound and which proteins are captured, offering practical guidance for PAL-AfBPP probe design. Limitations include that this is primarily a chemical biology and proteomics study conducted at the in vitro/biochemical level, with no human clinical data. The mechanistic link between QDAU5–Tβ4 interaction and angiogenesis regulation requires further validation in vivo.
Bioorganic chemistry · Feb 2026DOI ↗ In vitro
This study investigated, for the first time, how the small peptide Thymosin β4 (Tβ4) interacts with zinc ions (Zn²⁺) at physiological pH. Using a panel of biophysical techniques — including zeta potential analysis, dynamic light scattering (DLS), electrospray ionization mass spectrometry (ESI-MS), nuclear magnetic resonance (NMR) spectroscopy, and scanning electron microscopy with elemental mapping (SEM/EDS) — the researchers characterized the structural and chemical consequences of Zn²⁺ binding to this intrinsically disordered 43-amino-acid peptide. The study found that Zn²⁺ progressively neutralizes Tβ4's negative surface charge, triggering a sharp aggregation transition. ESI-MS identified peptide-to-zinc complexes at a 1:3 molar ratio, while DLS and SEM confirmed formation of compact, low-solubility supramolecular assemblies. NMR data indicated that Zn²⁺ binding does not induce folding of the peptide. Importantly, the study compared the experimentally determined critical aggregation concentration with known physiological extracellular Zn²⁺ levels, concluding that aggregation is unlikely under normal plasma or interstitial conditions but could occur in Zn-rich microenvironments such as the synaptic cleft. The authors propose that Zn²⁺-mediated Tβ4 assembly may be relevant in neurological or inflammatory contexts. This is a foundational biochemical characterization study with no direct in vivo or clinical component.
International journal of molecular sciences · Feb 2026DOI ↗ Animal only
This study investigated a novel hydrogel-based therapy for intrauterine adhesions (IUA), a condition where uterine scarring causes infertility. The researchers engineered a hydrogel combining two components: a bioactive extracellular matrix derived from decidualized endometrium (DEndo-UdECM) and the anti-fibrotic peptide Thymosin β4 (Tβ4), designed for sustained local release. Using a mouse model of IUA, the study reported that a single administration of the hydrogel restored normal endometrial tissue architecture, reduced fibrosis, and resulted in near-complete fertility recovery in treated animals. Mechanistic investigations suggested the hydrogel worked by shifting macrophage polarization toward an anti-inflammatory M2 phenotype, suppressing pyroptosis-driven inflammation, and inhibiting the TGF-β/Smad3 signaling pathway, which drives fibrotic scarring. The study's primary limitation is that all experimental work was conducted in a murine model, meaning the findings have not yet been validated in humans or large-animal models. Whether the regenerative and anti-fibrotic effects, as well as the fertility outcomes, would translate to human patients remains unknown. Nonetheless, the study provides a mechanistically detailed preclinical proof-of-concept for a biomaterial strategy targeting the root pathology of IUA.
Nature communications · Jan 2026DOI ↗ Review
This review synthesizes existing preclinical and emerging translational evidence on Thymosin β4 (Tβ4), a conserved 43-amino-acid peptide, and its N-terminal metabolite Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro), as potential therapeutic candidates in kidney disease. The authors map the intracellular and extracellular mechanisms of the Tβ4–Ac-SDKP axis, including its roles in actin sequestration, cytoprotection, anti-inflammatory signaling, and antifibrotic actions across both glomerular and tubular compartments. Evidence is evaluated across models of both acute and chronic kidney injury. The review acknowledges contradictory findings regarding fibrosis and proposes conceptual frameworks to explain bidirectional effects and model-dependent mechanisms. Translational considerations discussed include peptide pharmacokinetics, stability challenges, and drug delivery strategies. The authors note that key barriers to clinical translation remain, including the need for validation in additional clinically relevant models, resolution of peptide instability, and comprehensive safety profiling. As a narrative review, this paper does not generate new experimental data, and its conclusions are limited by the quality and heterogeneity of the underlying studies, most of which appear to be animal-based.
Review
This narrative review examines the potential role of therapeutic peptides in orthopaedic care, synthesizing preclinical and mechanistic literature across several peptide classes. The authors categorize peptides by their primary proposed function: wound-healing agents (BPC-157, TB-500, GHK-Cu), growth hormone secretagogues (ipamorelin, CJC-1295, tesamorelin, sermorelin, AOD-9604), recovery-enhancing peptides (epithalon, delta sleep-inducing peptide, pinealon), and neuroactive peptides (selank, semax, dihexa). The review describes how these compounds are theorized to interact with signaling pathways—including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK—to promote tissue regeneration, resolve inflammation, and support neuromuscular recovery. The authors acknowledge that, while preclinical evidence is promising, robust human clinical trial data are largely absent, representing a significant gap in the literature. Limitations include the review's reliance on animal and in vitro studies, the absence of a systematic search methodology, and the lack of direct clinical evidence supporting efficacy or safety in human orthopaedic populations. The authors call for future controlled trials to validate these mechanistic findings in clinical settings.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · Jan 2026DOI ↗ Review
This narrative review, aimed at orthopaedic and sports medicine physicians, synthesizes the existing biochemical and clinical literature on six commonly marketed injectable therapeutic peptides: BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conducted a PubMed literature search and evaluated evidence across preclinical and clinical settings. Key findings attributed to the reviewed studies include: BPC-157 showed potential in tendon and muscle repair in preclinical models, with one human case series reporting pain reduction after intra-articular knee injection, though that study had significant methodological limitations and no control group. TB-4 and TB-500 demonstrated angiogenesis and tissue repair effects in animal models, but no human orthopaedic data were identified, and both are banned in sport. CJC-1295 combined with ipamorelin improved muscle tension in a murine glucocorticoid-induced muscle loss model only. Tesamorelin holds FDA approval for HIV-associated lipodystrophy but lacks orthopaedic evidence. GHK-Cu showed wound healing and anti-inflammatory properties preclinically, with no clinical musculoskeletal data. The authors conclude that indications, safety profiles, and dosing for all these peptides remain undefined for orthopaedic use, and robust human trials are needed before clinical recommendations can be made.
The American journal of sports medicine · Jan 2026DOI ↗ Animal only
This study developed a novel low-temperature fabrication method for soluble microneedles (MNs) loaded with thymosin β4 (Tβ4), a peptide with known wound-healing and immunomodulatory properties. Traditional MN production methods involve conditions that can denature sensitive peptides, so the researchers used chitosan and sucrose to create stable, biocompatible MNs at lower temperatures. The resulting patches demonstrated uniform morphology, a high drug-loading capacity (~248 µg/patch), and rapid dissolution within one hour. In a mouse wound model, Tβ4-loaded MNs significantly enhanced wound healing compared to controls. To investigate the underlying mechanism, the study employed RNA sequencing and differentially expressed gene (DEG) analysis, identifying downregulated immune regulators Spp1, Vsig4, and IL22rα2 as potentially relevant targets. Subsequent in vitro experiments — including qPCR, western blot, and surface plasmon resonance (SPR) — demonstrated that Tβ4 specifically binds to Vsig4 (KD = 3.56 × 10⁻⁶ M) and IL22rα2 (KD = 9.69 × 10⁻⁶ M). A key limitation is that efficacy and mechanistic data are primarily derived from mouse models and cell-based assays, with no human clinical data reported. The findings offer insights into Tβ4's immunomodulatory targets and potential avenues for drug development.
Advanced healthcare materials · Dec 2025DOI ↗ Preclinical
This study investigated whether two peptides derived from Thymosin β4 (Tβ4) — TB500 and Ac-SDKP — could reduce Alzheimer's disease (AD)-related pathology using both cell-based and animal models. In vitro, the peptides were tested in Aβ25-35-treated HT22 neuronal cells and primary cortical neurons, where they were found to reduce neurite atrophy, restore cell viability, and modulate apoptosis-related gene expression. In BV2 microglia, the peptides suppressed LPS-induced nitric oxide production, reduced pro-inflammatory cytokines, and inhibited M1 microglial polarization. In the 5×FAD transgenic mouse model of AD, treated animals showed improved performance on the Morris water maze and novel object recognition tests compared to untreated counterparts. Immunohistochemical analyses indicated reduced glial activation and neuronal apoptosis in treated mice, along with restored axonal density in the perirhinal cortex. However, hippocampal amyloid-β plaque burden was not significantly changed. Transcriptomic profiling highlighted genes such as Foxb2 and Or2k2 as potentially relevant to the observed neuroprotective effects. Key limitations include the exclusive use of preclinical models (no human data), reliance on a single transgenic mouse strain, and the need for further mechanistic validation. No human trials were conducted.
International immunopharmacology · Dec 2025DOI ↗ ReviewPreprint
This review paper examines the pharmacological mechanisms, safety profiles, and regulatory status of both approved and unapproved peptide therapies relevant to sports medicine, musculoskeletal injury recovery, and athletic performance enhancement. The compounds reviewed span a wide spectrum — from FDA-approved agents such as tesamorelin and sermorelin, to gray-market compounds including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, and SS-31. The authors note that while many unapproved peptides show promising results in preclinical and animal models — including favorable tissue repair and metabolic effects — rigorous human safety and efficacy data remain scarce. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses how social media may amplify perceived benefits through placebo-related mechanisms. The paper also offers a clinical framework to guide patient conversations and support evidence-based decision-making. Key limitations include the inherent constraints of a narrative review design, reliance on heterogeneous preclinical data for unapproved compounds, and the absence of controlled human trials for most of the highlighted peptides.
Unknown journal · Dec 2025DOI ↗ In vitro
This study investigated how Thymosin β4 (Tβ4), a 43-amino-acid secreted peptide, may protect against hypoxia-induced blood-brain barrier (BBB) disruption using human brain microvascular endothelial cells (hBMVECs) as an in vitro model. The researchers exposed hBMVECs to hypoxic conditions to simulate aspects of ischemic injury and traumatic brain injury (TBI), then examined whether Tβ4 pretreatment could reverse resulting damage. They measured gene expression of tight junction proteins, Sphingosine 1-phosphate receptor 1 (S1PR1), endothelial cell permeability, and tight junction dynamics. The study found that Tβ4 pretreatment appeared to reverse hypoxia-induced impairment of BBB components, and identified S1PR1 as a potential mechanistic target. Notably, when S1PR1 was pharmacologically inhibited, Tβ4 lost its protective effect, suggesting S1PR1 signaling is required for Tβ4's action. The authors conclude that S1PR1 pathway modulation is central to hypoxia-induced BBB pathophysiology and propose Tβ4 as a candidate therapeutic agent warranting further investigation. Key limitations include the exclusive use of cell culture models, absence of animal or human data, and lack of in vivo validation of the proposed mechanism.
Scientific reports · Dec 2025DOI ↗ In vitro
This study investigated whether Tβ4-17, a small bioactive peptide derived from the precursor protein thymosin β4 and identified via iTRAQ technology, could enhance the sensitivity of cisplatin (DDP)-resistant ovarian cancer cells to chemotherapy. Using in vitro cell line models of DDP-resistant ovarian cancer, the researchers tested the combination of Tβ4-17 with DDP on cell proliferation, migration, and apoptosis. Results indicated that the combination significantly inhibited proliferation and migration of resistant cells while promoting apoptosis compared to either treatment alone. Mechanistically, the study found that NF-κB (specifically the p65 subunit) was highly expressed in DDP-resistant ovarian cancer cells, and that Tβ4-17 appeared to downregulate NF-κB p65 protein expression. These findings were supported by qRT-PCR, Western blot, CCK-8 assays, EDU fluorescence proliferation assays, and scratch migration assays, as well as experiments using NF-κB inhibitors and activators. Key limitations include reliance solely on in vitro cell line models with no animal or human data, and the absence of pharmacokinetic or safety assessments. The study suggests a potential mechanism by which Tβ4-17 may overcome chemoresistance in ovarian cancer but requires substantial further validation.
Medical oncology (Northwood, London, England) · Nov 2025DOI ↗ Preclinical
This study investigated the role of mast cell (MC)-derived thymosin β4 (Tβ4) in stress-induced intestinal barrier dysfunction in irritable bowel syndrome (IBS). Researchers measured Tβ4 levels in colonic mucus of IBS patients and used a combination of in vitro experiments, rodent models (including Tβ4-knockout rats and MC-deficient mice), and reconstitution experiments to examine mechanisms. The study found that Tβ4 levels were elevated in the colonic mucosa and intestinal MCs of IBS patients. In animal models, Tβ4 appeared to reduce tight junction proteins and the IL22RA1/Reg3γ cascade while increasing myosin light chain kinase activity, collectively impairing the epithelial barrier. Tβ4-deficient rats showed resistance to stress-induced barrier disruption, and reintroduction of Tβ4 or wild-type peritoneal MCs restored that disruption. Mechanistically, Tβ4 release from MCs was found to depend on corticotropin-releasing hormone receptor 1 signaling rather than classic degranulation, and its barrier-impairing effects were linked to inhibition of the IL22RA1/JAK1/STAT3 signaling pathway. Limitations include reliance on rodent models for mechanistic work, modest human clinical data, and the complexity of translating these findings to therapeutic applications.
World journal of gastroenterology · Nov 2025DOI ↗ Preclinical
This study investigated the role of Thymosin β4 (Tβ4) in breast cancer progression and its molecular mechanism. The researchers found that Tβ4 is significantly overexpressed in breast cancer tissues and cell lines, with high expression correlating with poorer clinical outcomes. Using functional experiments, the study showed that elevated Tβ4 promotes cancer cell proliferation, migration, epithelial-mesenchymal transition (EMT), and angiogenesis, while inhibiting apoptosis. Mechanistically, the study identified that Tβ4 directly regulates SLC7A11, a cystine/glutamate antiporter, which in turn enhances glutathione biosynthesis and suppresses lipid peroxidation — effectively inhibiting ferroptosis (an iron-dependent form of programmed cell death). Rescue experiments, conducted both in cell cultures (in vitro) and animal models (in vivo), demonstrated that silencing SLC7A11 reversed the cancer-promoting effects of Tβ4. The study concludes that a novel Tβ4/SLC7A11 signaling axis modulates ferroptosis resistance and contributes to breast cancer malignancy. Limitations include reliance on preclinical models, and no human clinical trials were conducted, leaving the translational relevance to patients yet to be established.
Cellular signalling · Sep 2025DOI ↗ Preclinical
This study investigated whether thymosin beta 4 (Tβ4), encoded by the gene TMSB4X, plays a role in Alzheimer's disease (AD) pathology and could serve as a potential intervention target. Researchers generated cerebral organoids ("mini-brains") from induced pluripotent stem cells (iPSCs) carrying familial AD (fAD)-associated mutations in the amyloid precursor protein (APP) gene. Using these organoids, they characterized dynamic changes in cellular states and found that mature neuron formation was markedly reduced in fAD organoids compared to healthy controls, alongside increased cellular senescence and beta-amyloid (Aβ) production. Notably, TMSB4X/Tβ4 expression was significantly decreased both in fAD organoid neurons and in excitatory neurons from post-mortem AD patient brain data. Treatment with Tβ4 protein appeared to rescue neurodevelopmental deficits and reduce Aβ formation in the fAD organoids. Corroborating findings were also reported in 5xFAD transgenic mice. The study concludes that Tβ4 may act as a neuroprotective factor capable of mitigating altered neurogenesis and AD pathology. Key limitations include the use of organoid and animal models rather than human clinical data, and the inherent complexity of translating organoid findings to human disease.
Stem cell reports · Aug 2025DOI ↗